Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,783 shares of the biotechnology company’s stock after selling 817 shares during the quarter. Yousif Capital Management LLC’s holdings in Sarepta Therapeutics were worth $1,837,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares during the period. Smartleaf Asset Management LLC grew its stake in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 216 shares during the period. Logan Capital Management Inc. acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $61,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of Sarepta Therapeutics by 274.5% during the 4th quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 387 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $36.18 on Monday. The firm has a market capitalization of $3.56 billion, a PE ratio of 28.94 and a beta of 0.61. Sarepta Therapeutics, Inc. has a one year low of $34.10 and a one year high of $173.25. The stock’s 50 day moving average price is $46.25 and its 200 day moving average price is $86.03. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.73 EPS. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SRPT shares. Piper Sandler dropped their target price on Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $183.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Royal Bank of Canada cut their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 7th. UBS Group decreased their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Finally, Morgan Stanley dropped their price target on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.